
HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc's (NASDAQ:ACAD) perhaps marks the end of the Alzheimer's disease psychosis (ADP) story for now.
However, looking beyond the ADP, the analysts think Acadia's pipeline still has possibilities in new indications like the Rett syndrome and for the label expansion of pimavanserin for the negative symptoms of schizophrenia.